ABSTRACT
Immune dysregulation in individuals with Down syndrome (DS) leads to an increased risk for hospitalization and death due to COVID-19 and may impair the generation of protective immunity after vaccine administration. The cellular and humoral responses of 55 DS patients who received a complete SARS-CoV-2 vaccination regime at one to three (V1) and six (V2) months were characterised. SARS-CoV-2-reactive CD4+ and CD8+ T lymphocytes with a predominant Th1 phenotype were observed at V1, and increased at V2. Likewise, a sustained increase of SARS-CoV-2-specific circulating Tfh (cTfh) cells was observed one to three months after vaccine administration. Specific IgG antibodies against SARS-CoV-2 S protein were detected in 96% and 98% of subjects at V1 and V2, respectively, though IgG titers decreased significantly between both timepoints.
SUMMARY The work shows the cellular and humoral responses to SARS-CoV-2 vaccination of individuals with Down syndrome (DS) after one to three (V1) and six (V2) months. An effective immune response after six months was observed in 98% of DS individuals.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants to A.A.: FIS PI19/01491 (Fondo de Investigacion Sanitaria del Instituto de Salud Carlos III with co-funding from the Fondo Europeo de Desarrollo Regional FEDER) and Sociedad Cooperativa de Viviendas Buen Suceso, S.Coop.Mad. To A.A. and F.S-M.: CIBER Cardiovascular from the Instituto de Salud Carlos III (Fondo de Investigacion Sanitaria del Instituto de Salud Carlos III with co-funding from the Fondo Europeo de Desarrollo Regional; FEDER). To F.S-M.: Fondos Supera COVID19 (Banco de Santander and CRUE), Ayuda Covid 2019 and Inmunovacter REACT-UE (Comunidad de Madrid). DRA was supported by the Fondo de Investigaciones Sanitarias (FIS grant PI19/00634, from the Ministerio de Economia y Competitividad (Instituto de Salud Carlos III) and co-funded by The European Regional Development Fund (ERDF) A way to make Europe and the Fondation Jerome Lejeune (grant no. 2021a-2069). FM is supported by the Jerome Lejeune Foundation (grant no. 2017b-1711). The Adult Down Syndrome Outpatient unit at Hospital Universitario de La Princesa is grateful to Licenciado don Jesus Coronado Hinojosa for his financial support of the research endeavors of our unit.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This project was approved by the institutional IRB at La Princesa University Hospital (register number: 4386), meets international standards of data protection and is in line with general good practice guidelines and those established in the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors